STOCKS TELEGRAPH

Tag: PSTI

  • Collaboration with Tnuva: Pluristem Therapeutics Inc. (PSTI) stock Surges Premarket

    On January 10, Pluristem Therapeutics Inc. (PSTI) announced its collaboration with Tnuva for establishing a cultured food platform. Consequently, the stock was trading at $1.85 apiece premarket at the last check on Monday.

    In the previous session, the stock traded between a high of $1.43 and a low of $1.52 at 88.07K shares. PSTI closed the session at $1.47 with a gain of 3.52% on Friday. Following the announcement, the stock gained a huge 25.85% premarket. At the time of writing, the stock was trading heavily at a before-hours volume of 1.8 million shares.

    More About PSTI

    The clinical-stage cell therapy development company, Pluristem Therapeutics Inc. was founded in 2001. Currently, its 32.1 million outstanding shares trade at a market capitalization of $47.19 million. Moreover, PSTI stock has lost 2.65% in the past few days with a slight gain of 0.68% year to date. In the past year, the stock subtracted a huge 82.69%.

    Collaboration with Tnuva

    According to Today’s announcement, the company has launched an innovative collaboration with the Tnuva Group. Under the collaboration, the companies will develop, manufacture, and commercialize cultured cell-based products for the food industry. Furthermore, the collaboration has commenced with the incorporation of a new company (NewCo). The NewCo will attain exclusive, global, royalty-bearing licensing rights for utilizing PSTI’s technology along with its intellectual property for use in cultured meat fields.

    As per pre-money valuation of $40 million, Tnuva will invest $7.5 million in NewCo. Added to this, Tnuva has an option of investing an additional $7.5 million in NewCo over a 12-month period after the closing. As per the terms of the agreement, PSTI will support the activities of NewCo concerned with its establishment and R&D. Further, NewCo will promote its mission with its own funding, resources, and management team. In exchange for the R&D platform, Tnuva will attain preferred marketing rights of NewCo’s developed products in Israel.

    In addition, NewCo’s Proof of Concept is expected in 2022 with the first raw cultured meat product launch in 2023.

    PSTI’s Other Developments

    On December 27, the company reported topline results from its Phase II studies of PLX-PAD cells intramuscular injections. The studies were evaluating the injections for the treatment of ARDS (Acute Respiratory Distress Syndrome) associated with Covid-19.

    According to the results, the study failed to achieve the primary endpoint of statistically significant improvement of Ventilator Free Days at 28 days.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • The key reason why Pluristem Therapeutics Inc. (Nasdaq: PSTI) shares dipped in the premarket trading today

    The key reason why Pluristem Therapeutics Inc. (Nasdaq: PSTI) shares dipped in the premarket trading today

    Pluristem Therapeutics Inc. (Nasdaq: PSTI)  share nose-dived in the premarket session after the announcement by a leading regenerative medicine firm building a marketplace for new biotherapeutic drugs that the Independent Data Management Committee (DMC) of its global pivotal Phase III trial for the treatment of critical limb ischemia (CLI) released its recommendation letter after an interim review.

    An unbiased DMC checked the clinical dataset to protect and examine the primary endpoint of amputation-free survival, identified as the time for significant amputation of the index leg or death.

    Based on the evaluation, the DMC concluded that the CLI thesis is unlikely to reach the primary endpoint at the time of the final report. The lower than predicted case occurrence in the placebo community decreased the analysis’s predictive capacity to reach its primary endpoint.

    DMC noted that PLX-PAD was well tolerated and that no significant safety issues were posed during the analysis.

    Following the advice of the DMC, the Organization agreed to terminate the CLI report. The business appears to be blinded to clinical evidence from the CLI report.